肝内胆管癌的外科治疗：何去何从。
Surgical Management of Intrahepatic Cholangiocarcinoma: Quo Vadis.
作者信息
Moris Dimitrios
机构信息
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
出版信息
Cancers (Basel). 2023 Sep 23;15(19):4691. doi: 10.3390/cancers15194691.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy related to very high mortality rates [...].
摘要
肝内胆管癌（ICC）是第二常见的原发性肝癌，死亡率极高[...]。
相似文献
1
Surgical Management of Intrahepatic Cholangiocarcinoma: Quo Vadis.肝内胆管癌的外科治疗：何去何从。
Cancers (Basel). 2023 Sep 23;15(19):4691. doi: 10.3390/cancers15194691.
2
Intrahepatic Cholangiocarcinoma.肝内胆管癌
Semin Intervent Radiol. 2020 Dec;37(5):475-483. doi: 10.1055/s-0040-1719188. Epub 2020 Dec 11.
3
Surgical treatment of intrahepatic cholangiocarcinoma in the USA.美国肝内胆管癌的外科治疗
J Hepatobiliary Pancreat Sci. 2015 Feb;22(2):124-30. doi: 10.1002/jhbp.157. Epub 2014 Sep 4.
4
Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments.当前肝内胆管癌的治疗策略：从手术切除到姑息治疗。
Radiol Oncol. 2020 Jul 29;54(3):263-271. doi: 10.2478/raon-2020-0045.
5
[Progress on surgical treatment of intrahepatic cholangiocarcinoma].[肝内胆管癌的外科治疗进展]
Zhonghua Wai Ke Za Zhi. 2019 Apr 1;57(4):241-246. doi: 10.3760/cma.j.issn.0529-5815.2019.04.001.
6
Surgical options for intrahepatic cholangiocarcinoma.肝内胆管癌的手术治疗方案
Hepatobiliary Surg Nutr. 2017 Apr;6(2):79-90. doi: 10.21037/hbsn.2017.01.06.
7
Surgical Aspects of Intrahepatic Cholangiocarcinoma.肝内胆管癌的外科手术相关方面
Cancers (Basel). 2022 Dec 19;14(24):6265. doi: 10.3390/cancers14246265.
8
[Viewpoint of systematic lymphadenectomy for intrahepatic cholangiocarcinoma patients].[肝内胆管癌患者系统性淋巴结清扫术的观点]
Zhonghua Wai Ke Za Zhi. 2019 Apr 1;57(4):247-252. doi: 10.3760/cma.j.issn.0529-5815.2019.04.002.
9
Linoleic acid pathway disturbance contributing to potential cancerization of intrahepatic bile duct stones into intrahepatic cholangiocarcinoma.亚麻酸途径紊乱促进肝内胆管结石向肝内胆管癌的潜在癌变。
BMC Gastroenterol. 2022 May 30;22(1):269. doi: 10.1186/s12876-022-02354-2.
10
Prognostic impact of hepatitis B or C on intrahepatic cholangiocarcinoma.乙型肝炎或丙型肝炎对肝内胆管癌的预后影响。
Korean J Intern Med. 2020 May;35(3):566-573. doi: 10.3904/kjim.2018.062. Epub 2020 Jan 10.
引用本文的文献
1
: A Novel Target in Intrahepatic Cholangiocarcinoma and its Role in Modulating Tumor Behavior.肝内胆管癌的一个新靶点及其在调节肿瘤行为中的作用
Clin Med Insights Oncol. 2025 Aug 17;19:11795549251360481. doi: 10.1177/11795549251360481. eCollection 2025.
2
Association of α-SMA/FAP-positive cancer-associated fibroblasts with clinicopathological features and prognosis in extrahepatic cholangiocarcinoma.α-SMA/FAP阳性癌相关成纤维细胞与肝外胆管癌临床病理特征及预后的相关性
Diagn Pathol. 2025 Jul 17;20(1):85. doi: 10.1186/s13000-025-01691-6.
3
Liver Transplantation for Non-hepatocellular Carcinoma: The Role of Immune Checkpoint Inhibitors.非肝细胞癌的肝移植：免疫检查点抑制剂的作用
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102558. doi: 10.1016/j.jceh.2025.102558. Epub 2025 Mar 27.
4
ADAMDEC1 promotes the malignant progression of cholangiocarcinoma by regulating NF-κB signaling pathway.ADAMDEC1通过调节NF-κB信号通路促进胆管癌的恶性进展。
Sci Rep. 2025 Jan 4;15(1):817. doi: 10.1038/s41598-025-85241-6.
5
Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation.胆管癌：包括肝移植在内的手术选择现状
Cancers (Basel). 2024 May 21;16(11):1946. doi: 10.3390/cancers16111946.
本文引用的文献
1
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians.肝内胆管癌治疗进展：临床医生当前及未来治疗前景概述
CA Cancer J Clin. 2023 Mar;73(2):198-222. doi: 10.3322/caac.21759. Epub 2022 Oct 19.
2
A simple scoring system to estimate perioperative mortality following liver resection for primary liver malignancy-the Hepatectomy Risk Score (HeRS).一种用于评估原发性肝癌肝切除术后围手术期死亡率的简单评分系统——肝切除风险评分（HeRS）。
Hepatobiliary Surg Nutr. 2021 Jun;10(3):315-324. doi: 10.21037/hbsn.2020.03.12.
3
Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?肿瘤负荷决定肝内胆管癌切除患者的预后：一种指导术后辅助化疗的工具？
Ann Surg Oncol. 2021 Apr;28(4):1970-1978. doi: 10.1245/s10434-020-09393-7. Epub 2020 Dec 1.
4
Using Hepatocellular Carcinoma Tumor Burden Score to Stratify Prognosis after Liver Transplantation.使用肝细胞癌肿瘤负担评分对肝移植后的预后进行分层
Cancers (Basel). 2020 Nov 14;12(11):3372. doi: 10.3390/cancers12113372.
5
Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria.总体肿瘤负担决定了米兰标准以外的多结节性肝细胞癌患者切除术后的结局。
Ann Surg. 2020 Oct;272(4):574-581. doi: 10.1097/SLA.0000000000004346.
6
Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.肝内胆管癌切除术后生存的验证预后模型的质量和性能：一项系统评价和荟萃分析。
HPB (Oxford). 2021 Jan;23(1):25-36. doi: 10.1016/j.hpb.2020.07.007. Epub 2020 Aug 25.
7
A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis.一种使用机器学习技术对肝内胆管癌表型进行的新分类：一项国际多机构分析。
Ann Surg Oncol. 2020 Dec;27(13):5224-5232. doi: 10.1245/s10434-020-08696-z. Epub 2020 Jun 3.
8
Primary Liver Cancers: Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.原发性肝癌：肝内胆管细胞癌和肝细胞癌。
Surg Clin North Am. 2020 Jun;100(3):535-549. doi: 10.1016/j.suc.2020.02.013. Epub 2020 Apr 16.
9
The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis.系统性免疫炎症指数预测肝内胆管细胞癌预后：国际多机构分析。
HPB (Oxford). 2020 Dec;22(12):1667-1674. doi: 10.1016/j.hpb.2020.03.011. Epub 2020 Apr 4.
10
Hepatocellular carcinoma tumour burden score to stratify prognosis after resection.肝细胞癌肿瘤负荷评分用于分层切除术后的预后。
Br J Surg. 2020 Jun;107(7):854-864. doi: 10.1002/bjs.11464. Epub 2020 Feb 14.
Zotero 插件